SCHEMBL12656080

SCHEMBL12656080

CC(=O)c1ccc(S(=O)(=O)N2CCC3(CC2)OCCN3C(=O)OCc2ccccc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ TGM2 P21980 6/20 0.44
▸ F13A1 P00488 5/20 0.44
▸ TGM1 P22735 5/20 0.44
▸ LMNA P02545 1/20 0.44
▸ KMT2A Q03164 2/20 0.42
▸ POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12622090 0.85 ALDH1A1 (0.49) ALDH1A1NPC1MAPTRAB9ASMN1; SMN2
SCHEMBL13035914 0.80 HCRTR1 (0.50) ALDH1A1MAPTSMN1; SMN2KMT2APOLB
SCHEMBL12622116 0.80 ALDH1A1 (0.57) ALDH1A1NPC1MAPTRAB9ASMN1; SMN2
SCHEMBL12626965 0.77 ALDH1A1 (0.50) ALDH1A1NPC1MAPTRAB9ASMN1; SMN2
SCHEMBL12656081 0.76 MEN1 (0.49) NPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL12621830 0.76 ALDH1A1 (0.59) ALDH1A1NPC1MAPTRAB9ASMN1; SMN2
SCHEMBL13353201 0.76 LMNA (0.60) ALDH1A1NPC1MAPTRAB9ASMN1; SMN2
SCHEMBL12624082 0.75 ALDH1A1 (0.56) ALDH1A1NPC1MAPTRAB9ASMN1; SMN2
SCHEMBL12656079 0.75 MEN1 (0.49) NPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL12625901 0.74 POLB (0.56) ALDH1A1SMN1; SMN2LMNAKMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2488177-B1 FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC PAIN THERAPEUTICS INC (US) 2016-10-12 — — EP disclosed
US-20160251374-A1 FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC BURNS BARBIER LINDSAY (US) 2016-09-01 — — US disclosed
US-9340558-B2 Filamin a binding anti-inflammatory and analgesic PAIN THERAPEUTICS INC. (US) 2016-05-17 — — US disclosed
EP-2918587-A2 Filamin a binding anti-inflammatory and analgesic Pain Therapeutics, Inc. (US) 2015-09-16 — — EP disclosed
US-20140113895-A1 FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC PAIN THERAPEUTICS, INC. 2014-04-24 — — US disclosed
US-8653068-B2 Filamin A binding anti-inflammatory and analgesic PAIN THERAPEUTICS, INC. (US) 2014-02-18 — — US disclosed
US-20110105487-A1 FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC PAIN THERAPEUTICS 2011-05-05 — — US disclosed
US-20110105481-A1 FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC PAIN THERAPEUTICS 2011-05-05 — — US disclosed
WO-2010051497-A1 FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC PAIN THERAPEUTICS, INC. (US) 2010-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160251374-A1 FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC FLNA, FLNB, OPRK1 ALDH1A1 2575/4885NPC1 3168/4885MAPT 3656/4885
US-20110105487-A1 FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC FLNA, FLNB, FPR1 ALDH1A1 3041/4885NPC1 2479/4885MAPT 2837/4885
US-20110105481-A1 FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC FLNA, FLNB, OPRK1 ALDH1A1 2575/4885NPC1 3168/4885MAPT 3656/4885
US-20140113895-A1 FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC FLNA, FLNB, OPRK1 ALDH1A1 2575/4885NPC1 3168/4885MAPT 3656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback